February 14, 2020 / 11:52 AM / 3 days ago

BRIEF-Epizyme Announces FDA Acceptance Of NDA For Filing With Priority Review For Tazverik (Tazemetostat) For The Treatment Of Follicular Lymphoma

Feb 14 (Reuters) - Epizyme Inc:

* EPIZYME ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR FILING WITH PRIORITY REVIEW FOR TAZVERIK™ (TAZEMETOSTAT) FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

* EPIZYME INC - APPROVAL WOULD EXPAND TAZVERIK LABEL INTO SECOND INDICATION

* EPIZYME INC - PDUFA TARGET ACTION DATE SCHEDULED FOR JUNE 18, 2020 FOR TAZVERIK Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below